A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood

European Journal of Haematology

Volumn 64, Issue 4, 2000, Pages 252-258

  Fujimaki, Shin ichi ^a   Funato, T ^a   Harigae, H ^a   Imaizumi, M ^a   Suzuki, H ^a   Kaneko, Y ^b   Miura, Y ^a   Sasaki, T ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Acute myelogenous leukaemia (AML); AML1 ET0 (MTGS); Minimal residual disease (MRD); Real time quantitative PCR system; RT PCR; T1(8; 21)

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CHILD; CHIMERA; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE PROBES; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034037358     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90091.x     Document Type: Article

References (36)

1. 1. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992;80:1825-1831.
2. 2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626-629.
3. 3. Berger R, Flandrin G, Bernheim A, et al. Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogenet 1987;29:9-21.
4. 4. Fenaux P, Preudhomme C, Lai JL, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol 1989;73:61-67.
5. 5. Kita K, Shirakawa S, kamada N, the Japanese cooperative group of leukemia/lymphoma. Cellular characteristics of acute myeloblastic leukemia assosiated with t(8;21)-(q22;q22). Leuk Lymphoma 1994;13:229-234.
6. 6. Swirsky DM, Li YS, Matthews JG, Flemans RJ, Ress JKH, Hayhoe FGJ. 8;21 translocation in acute granulocytic leukemia: cytological, cytochemical and clinical features. Br J Haematol 1984;56:199-213.
7. 7. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416-1434.
8. 8. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:9717-9721.
9. 9. Siebert PD, Larrick JW. Competitive PCR. Nature 1992;359:557-558.
10. 10. Raeymaekers L. A commentary on the practical applications of competitive PCR. Genome Res 1995;5:91-94.
11. 11. Miyamoto T, Nagafuji K, Harada M, et al. Quantitative analysis of AML 1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukemia. Br J Haematol 1995;91:132-138.
12. 12. Muto A, Mori S, Matsushita H, et al. Serial quantitative of minimal residual disease of t(8;21) acute myelogenous leukemia with RT-competitive PCR assay. Br J Haematol 1996;95:85-94.
13. 13. Tobal K, Liu-Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996;88:3704-3709.
14. 14. Miyamoto T, Nagafuji T, Harada M, Niho Y. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Leuk Lymphoma 1997;25:69-75.
15. 15. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Bio/Technology 1992;10:413-417.
16. 16. Lee LG, Connell R, Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucl Acids Res 1993;21:3761-3766.
17. 17. Heid CA, Stevens J, Livak KJ, Willams PM. Real time quantitative PCR. Genome Res 1996;6:986-994.
18. 18. Gibson UEM, Heid CA, Wiliams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995 1001.
19. 19. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998;12:1482-1489.
20. 20. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991;77:2031-2036.
21. 21. Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 1980;56:344-350.
22. 22. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valeni F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-1086.
23. 23. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993;82:712-715.
24. 24. Chang KS, Fan YH, Stass SA, et al. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993;8:983-988.
25. 25. Downing JR, Head DR, Curcio-Brint AM, et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993;81:2860-2865.
26. 26. Kozu T, Miyoshi H, Shimizu K, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993;82:1270-1276.
27. 27. Maruyama F, Stass SA, Estey EH, et al. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 1994;8:40-45.
28. 28. Zhang T, Hillion J, Tong JH, et al. AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21). Leukemia 1994;8:729-734.
29. 29. Kusec R, Laczika K, Knobl P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:735-739.
30. 30. Guerrasio A, Rosso C, Martinelli G, et al. Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukemia in continuous clinical remission. Br J Haematol 1995;90:364-368.
31. 31. Kwong YL, Chan V, Wong KF, Chan TK. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer 1995;75:821-825.
32. 32. Satake N, Maseki N, Kozu T, et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol 1995;91:892-898.
33. 33. Lynas C, Howe D, Sweeney M, Wagstaff M. t(8;21) detection by RT-PCR: an improved primer set convenient for the routine laboratory. Br J Haematol 1995;91:924-926.
34. 34. Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996;88:2183-2191.
35. 35. Tighe JE, Calabi F. Alternative, out-of frame runt/MTG8 transcripts are encoded by the derivative(8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood 1994;84:2115 2121.
36. 36. Saunders MJ, Tobal K, Keeney S, Liu Yin JA. Expression of diverse AML1/MTG8 transcripts is aconsisitent feature in acute myeloid leukemia with t(8;21) irrespective of disease phase. Leukemia 1996;10:1139-1142.